PPAR Modulators and PPAR Pan Agonists for Metabolic Diseases: The Next Generation of Drugs Targeting Peroxisome Proliferator-Activated Receptors?

By  

Current Topics in Medicinal Chemistry, Vol. 8, Iss. 9, 2008-06 ,pp. : 728-749

Bentham Science Publishers

Access to resources Recommend Favorite

Peroxisome Proliferator-Activated Receptor (PPAR) Gamma Agonists as Therapeutic Agents for Cardiovascular Disorders: Focus on Atherosclerosis

By  

Current Pharmaceutical Design, Vol. 23, Iss. 7, 2017-04 ,pp. : 1119-1124

Bentham Science Publishers

Access to resources Recommend Favorite

Docking, Synthesis and Anti-Diabetic Activity of Novel Sulfonylhydrazone Derivatives Designed as PPAR-Gamma Agonists

By  

Current Topics in Medicinal Chemistry, Vol. 12, Iss. 19, 2012-10 ,pp. : 2037-2048

Bentham Science Publishers

Access to resources Recommend Favorite

Mayday for Dual PPAR Agonists: Once-Hyped Diabetes Therapies in Their Death Throes?

By Adis International Limited  

Pharmaceutical & Diagnostic Innovation, Vol. 4, Iss. 6, 2006-01 ,pp. : 7-10

Adis International

Access to resources Recommend Favorite

Use of Clinically Available PPAR Agonists for Heart Failure; Do the Risks Outweigh the Potential Benefits?

By  

Current Molecular Pharmacology, Vol. 5, Iss. 2, 2012-06 ,pp. : 255-263

Bentham Science Publishers

Access to resources Recommend Favorite